The historical data trend for PRA Health Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PRA Health Sciences's EV-to-EBIT
For the Diagnostics & Research subindustry, PRA Health Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRA Health Sciences's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PRA Health Sciences's EV-to-EBIT falls into.
PRA Health Sciences's current Enterprise Value is $11,473 Mil.
PRA Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $313 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRA Health Sciences (NAS:PRAH) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PRA Health Sciences's Enterprise Value for the quarter that ended in Mar. 2021 was $10,699 Mil.
PRA Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $313 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRA Health Sciences EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of PRA Health Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
PRA Health Sciences (PRA Health Sciences) Business Description
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRAH has been successfully added to your 